Search

Displaying results 4481 - 4490 of 10000 in total
  1. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.

  2. Drug

    N-methylnicotinamide

    go.drugbank.com/drugs/DB08840
    Investigational

    N-methylnicotinamide is an experimental drug with no approved indication or marketed formulation. … It is a metabolite of niacinamide/nicotinamide and niacin/nicotinic acid (vitamin B3), and as such N-methylnicotinamide is used to diagnose niacin deficiency by measuring N-methylnicotinamide in the urine

    Synonyms: N-Methyl nicotineamide, 3-(N-Methylcarbamoyl)pyridine
  3. Drug

    Tofisopam

    go.drugbank.com/drugs/DB08811
    Investigational

    The D-enantiomer ([dextofisopam]) is currently in phase II trials in the U.S. for the treatment of irritable bowel syndrome. … Although Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe.

  4. Drug

    Oxantel

    go.drugbank.com/drugs/DB13670
    Investigational

    Oxantel is an anthelmintic drug that targets parasitic acetylcholine receptors.[A275093, A275098]

  5. Drug

    Pucotenlimab

    go.drugbank.com/drugs/DB17552
    ApprovedInvestigational

    It received its first global approval in China in July 2022 for the treatment of solid tumours.[A257296] It is being investigated in other cancers.

  6. Drug

    D-glyceraldehyde 3-phosphate

    go.drugbank.com/drugs/DB02263
    Experimental

    An aldotriose which is an important intermediate in glycolysis and in tryptophan biosynthesis.

  7. Drug

    Abafungin

    go.drugbank.com/drugs/DB06395
    Experimental

  8. Drug

    Ubenimex

    go.drugbank.com/drugs/DB03424
    Investigational

    It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. It is being studied for use in the treatment of acute myelocytic leukemia.

  9. Drug

    CTS-21166

    go.drugbank.com/drugs/DB06073
    Investigational

    In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability … , and oral availability; all of these have met the requirements of an ideal oral drug candidate.

  10. Drug

    Xanthine

    go.drugbank.com/drugs/DB02134
    Investigational

    The methylated xanthine compounds caffeine, theobromine, and theophylline and their derivatives are used in medicine for their bronchodilator effects. (Dorland, 28th ed) … It is an intermediate in the degradation of adenosine monophosphate to uric acid, being formed by oxidation of hypoxanthine.